POSSIBILITIES OF USING PROBIOTICS FOR HELICOBACTER PYLORI ERADICATION: MAASTRICHT V CONSENSUS CONFERENCE RECOMMENDATIONS

Download full text PDF
Issue: 
1
Year: 
2017

Professor V. Tsukanov, MD; Professor E. Kasparov, MD; A. Vasyutin, Candidate of Medical Sciences; Yu. Tonkikh, Candidate of Medical Sciences Research Institute of Medical Problems of the North, Krasnoyarsk Research Center, Siberian Branch of the Russian Academy of Sciences, Krasnoyarsk

The new European consensus for the management of patients with Helicobacter pylori (Hp)-associated diseases draws attention to the fact that the stomach has a large number of microorganisms that can influence the development of abnormalities. The use of probiotics contributes to a reduction in the incidence of side effects and enhances the effectiveness of Hp eradication.

Keywords: 
gastroenterology
Helicobacter pylori
microbiota
eradication
probiotics
consensus



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Malfertheiner P., Megraud F., O'Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht V / Florence Consensus Report // Gut. – 2017; 66 (1): 6–30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
  2. Bik E., Eckburg P., Gill S. et al. Molecular analysis of the bacterial microbiota in the human stomach // Proc. Natl. Acad. Sci. USA. – 2006; 103 (3): 732–7.
  3. Cao L., Yu J. Effect of Helicobacter pylori Infection on the Composition of Gastric Microbiota in the Development of Gastric Cancer // Gastrointest. Tumors. – 2015; 2 (1): 14–25.
  4. Khosravi Y., Dieye Y., Poh B. et al. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients // Sci. World J. – 2014; 2014: 610421.
  5. Sheh A., Fox J. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis // Gut Microbes. – 2013; 4 (6): 505–31.
  6. Butorin N.N., Bichurina T.B., Tsukanov V.V. i dr. Rasprostranennost' i klinicheskie aspekty pischevoda Barretta u naselenija Vostochnoj Sibiri // Ter. arh. – 2013; 1: 62–5.
  7. Tsukanov V.V., Tret'jakova O.V., Amel'chugova O.S. i dr. Rasprostranennost' atroficheskogo gastrita tela zheludka u naselenija g. Krasnojarska starshe 45 let // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2012; 4: 27–31.
  8. Tsukanov V.V., Seliverstova E.V., Dogadin S.A. Pokazateli lipidnogo sostava syvorotki krovi i zhelchi pri zabolevanijah zhelchevyvodjaschih putej u bol'nyh saharnym diabetom // Ter. arh. – 2005; 2: 15–8.
  9. Ageeva E.S., Shtygasheva O.V., Tsukanov V.V. i dr. Immunologicheskie osobennosti techenija gastroduodenal'noj patologii u zhitelej Hakasii // Immunologija. – 2009; 3: 162–4.
  10. Ageeva E.S., Shtygasheva O.V., Rjazantseva N.V. i dr. Molekuljarno-geneticheskie faktory, vlijajuschie na ishod infitsirovanija Helicobacter pylori u zhitelej Respubliki Hakasija // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2010; 4: 16–21.
  11. Dicksved J., Lindberg M., Rosenquist M. et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls // J. Med. Microbiol. – 2009; 58 (Pt. 4): 509–16.
  12. Eun C., Kim B., Han D. et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods // Helicobacter. – 2014; 19 (6): 407–16.
  13. Lofgren J., Whary M., Ge Z. et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia // Gastroenterology. – 2011; 140 (1): 210–20.
  14. Jernberg C., Löfmark S., Edlund C. et al. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota // ISME J. – 2007; 1 (1): 56–66.
  15. Ladirat S., Schols H., Nauta A. et al. High-throughput analysis of the impact of antibiotics on the human intestinal microbiota composition // J. Microbiol. Methods. – 2013; 92 (3): 387–97.
  16. Engelbrektson A., Korzenik J., Pittler A. et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy // J. Med. Microbiol. – 2009; 58 (Pt. 5): 663–70.
  17. Lv Z., Wang B., Zhou X. et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A metaanalysis // Exp. Ther. Med. – 2015; 9 (3): 707–16.
  18. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther. – 2010; 32 (9): 1069–79.
  19. Zhang M., Qian W., Qin Y. et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis // World J. Gastroenterol. – 2015; 21 (14): 4345–57.
  20. Marshall B., Warren J. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration // Lancet. – 1984; 1 (8390): 1311–5.
  21. Tsukanov V.V., Kasparov E.V., Vasjutin A.V. i dr. Mikrobiom zheludka: razvitie revoljutsii // Farmateka. – 2016: 15: 78–81.
  22. Sugano K., Tack J., Kuipers E. et al. Kyoto global consensus report on Helicobacter pylori gastritis // Gut. – 2015; 64 (9): 1353–67.